ALSO NOTED: Actavis shareholder pushes bolder strategy; Texas lawmakers back $3B cancer initiative; and much more...

> Live from BIO: A total of 22,366 people turned out for BIO 2007, a 15 percent increase over last year's conference. A third of the attendees came from outside the U.S. Release

> The largest shareholder in Finland's Actavis Group is bidding to buy up all remaining Class A shares in a bid to push the company to adopt a bolder corporate strategy. Report

> Support for a $3 billion effort to find a cure for cancer in Texas has gained support in the state House. Report

> Eli Lilly has followed IBM in laying out a formal policy excluding genetic data from decisions about employment and insurance coverage. Report

> Geron is advancing plans to file an IND with the FDA for an embryonic stem cell therapy for spinal injuries. Report

> Cell Genesys has outlined three trials underway for its leukemia drug GVAX. Report

> Canada's Asmacure Ltée announced a Series A round of financing of $9 million involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. Release

> Drug Royalty Corporation has acquired the future right to receive royalties on the sale of Enbrel from the Massachusetts General Hospital. Release

> Evotec announced today that Panacos Pharmaceuticals has extended its ongoing discovery collaboration with Evotec into its fourth year. Release 

And Finally… Swedish smokeless tobacco--called snus--is far less likely to cause cancer than traditional tobacco, according to physicians writing in The Lancet. Report